Navigation Links
BioMarin Announces Third Quarter 2010 Financial Results
Date:10/28/2010

t income is detailed in the table provided near the end of the press release.

GAAP net income for the nine months ended September 30, 2010 was $218.0 million ($1.74 per diluted share), compared to GAAP net loss of $5.2 million ($0.05 per diluted share) for the nine months ended September 30, 2009.  Non-GAAP net income was $23.4 million ($0.22 per diluted share) for the nine months ended September 30, 2010, compared to non-GAAP net income of $33.9 million ($0.33 per diluted share) for the nine months ended September 30, 2009.

As of September 30, 2010, BioMarin had cash, cash equivalents and short and long-term investments totaling $440.9 million, as compared to $455.4 million at the end of June 30, 2010.  

"In the third quarter, we saw strong commercial performance, despite being a seasonally weaker quarter.  During the quarter, based upon, among other things, our expectations to generate taxable income for the foreseeable future, we reversed most of our deferred tax asset valuation allowance which resulted in a one-time credit totaling $223.1 million," said Jean-Jacques Bienaime, Chief Executive Officer of BioMarin.  "Our pipeline has advanced tremendously over the last few months as highlighted at our recent R&D Day, and we are committed to investing in advancing the pipeline over the next two years to drive future growth.  We look forward to keeping you updated on the many clinical milestones expected in the coming year."

Net Product Revenue (in millions)Three Months Ended September 30,Nine Months Ended September 3020092010$ Change% Change20092010$ Change% ChangeNaglazyme (1) $

42.1$

51.7$

9.622.8%$

124.3$

147.5$

23.218.7%Kuvan (2) 21.726.24.520.7%54.172.118.033.3%Firdapse (3) −2.22.2N/A−3.43.4N/A(1)Changes in foreign currency rates, net of hedges, had a positive $0.1 million impact on Naglazyme sales in the three months ended September
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. BioMarin to Host a Research and Development Day on October 19th
2. BioMarin Appoints William Young and Kenneth Bate to Its Board of Directors
3. BioMarin to Present at the UBS Global Life Sciences Conference
4. BioMarin to Present at the Stifel Nicolaus Healthcare Conference
5. BioMarin Receives Orphan Drug Designation from the FDA for BMN-701 for the Treatment of Pompe Disease
6. BioMarin Acquires ZyStor Therapeutics, Inc.
7. BioMarin Initiates Phase 3b Study to Evaluate the Effects of Kuvan on Neurophychiatric Symptoms in Subjects with PKU
8. BioMarin to Acquire LEAD Therapeutics
9. BioMarin to Present at the Credit Suisse Healthcare Conference
10. BioMarin Announces Third Quarter 2009 Financial Results
11. BioMarin to Present at the Oppenheimer Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... -- Actavis plc (NYSE: ACT ) announced today ... and Drug Administration (FDA) as a twice-daily, oral ... with diarrhea (IBS-D). VIBERZI (eluxadoline) has mixed opioid ... a delta receptor antagonist, and a kappa receptor ... "The FDA,s approval of VIBERZI is ...
(Date:5/27/2015)... , May 27, 2015 OpportunityAnalyzer: Sepsis ... Sepsis patients suffer from a series of diverse ... toxins in the blood or tissues, which cause a ... leading to mortality rates near 50% depending on disease ... national healthcare systems of the global marketplace, which for ...
(Date:5/27/2015)... May 27, 2015 The prevalence of cardiovascular ... accelerated aging of population and changes in consumption concept, ... been growing year after year, thereby promoting the development ... in China totaled 454,505 in ... interventional cardiovascular device industry there was worth RMB20.12 billion. ...
Breaking Medicine Technology:Actavis Receives FDA Approval for VIBERZI (eluxadoline) for the Treatment of Irritable Bowel Syndrome with Diarrhea (IBS-D) in Adults 2Actavis Receives FDA Approval for VIBERZI (eluxadoline) for the Treatment of Irritable Bowel Syndrome with Diarrhea (IBS-D) in Adults 3Actavis Receives FDA Approval for VIBERZI (eluxadoline) for the Treatment of Irritable Bowel Syndrome with Diarrhea (IBS-D) in Adults 4Actavis Receives FDA Approval for VIBERZI (eluxadoline) for the Treatment of Irritable Bowel Syndrome with Diarrhea (IBS-D) in Adults 5OpportunityAnalyzer: Sepsis - Opportunity Analysis and Forecasts to 2021 2OpportunityAnalyzer: Sepsis - Opportunity Analysis and Forecasts to 2021 3OpportunityAnalyzer: Sepsis - Opportunity Analysis and Forecasts to 2021 4China Interventional Cardiovascular Device Industry Report, 2014-2017 2China Interventional Cardiovascular Device Industry Report, 2014-2017 3
... Alere Health, LLC announced today that it has ... Health Information Products Certification for Health Information Line. ... a 24/7 nurseline staffed by highly experienced, registered ... decisions by providing immediate clinical support for everyday ...
... BOTHELL, Wash., April 6, 2011 BioLife Solutions, Inc. ... grade biopreservation media products for cells and tissues, today ... ended March 31, 2011. This represents 6% sequential growth ... growth from the first quarter of 2010.   ...
Cached Medicine Technology:Alere Earns NCQA Health Information Products Certification for Health Information Line 2BioLife Solutions Announces Record Quarterly Revenue 2BioLife Solutions Announces Record Quarterly Revenue 3BioLife Solutions Announces Record Quarterly Revenue 4
(Date:5/27/2015)... 27, 2015 Cincinnati Veterans Affairs Women’s Health ... Veterans (CERV) Foundation is proud to host the first annual ... Veterans June 11 at the Freedom Center from 6 p.m. ... be the emcee. , This event honors and celebrates ... nation. The banquet is free to the first 150 ...
(Date:5/27/2015)... May 27, 2015 Genius Monkey is ... advanced programmatic marketing technology, they have boosted sales for ... on a regional level for seven Utah-based dealers. ... through television and radio media. In 2014 the Utah ... help of Genius Monkey , shifted their marketing ...
(Date:5/27/2015)... CA (PRWEB) May 27, 2015 With ... total communication environment where the message is not only heard ... toy, drawing, or virtually any motivating image. This award-winning and ... to offer. , Now, using InnerVoice Sender app ... can be sent to a learner remotely for no additional ...
(Date:5/27/2015)... May 27, 2015 With a prevalently ... poll conducted during the "ACA - Controlling the Chaos" ... 75% are currently in the process of researching ... were confidently prepared for the reporting mandates. , According ... the webinar, those who are currently vetting ACA reporting ...
(Date:5/27/2015)... SmarterSkin, http://www.smarterskindermatology.com , is taking skin care ... makes it easier for patients to find skin care products ... Sejal Shah is a cosmetic dermatologist based in New York ... test. This revolutionary DNA test uses 16 genetic markers to ... , 1. Firmness and elasticity , 2. Glycation , ...
Breaking Medicine News(10 mins):Health News:Cincinnati VA Women’s Health Clinic Celebrates Women Veterans at Awards Banquet 2Health News:Genius Monkey Boosts Utah Honda Dealers Website Traffic 142% 2Health News:Newly Released: InnerVoice Sender App Ups the Ante in Communication Technology for Autism with Remote Prompting 2Health News:Newly Released: InnerVoice Sender App Ups the Ante in Communication Technology for Autism with Remote Prompting 3Health News:Newly Released: InnerVoice Sender App Ups the Ante in Communication Technology for Autism with Remote Prompting 4Health News:Employers are On Track for ACA Reporting According to Businessolver Poll 2Health News:SmarterSkin Dermatology is Now Offering Skin DNA Analysis 2
... with language problems might have a lot in common with ... Impairment (SLI) // and they feel that these findings could ... best treatments for individual components of the condition. ,Researchers ... key language center in the brain -- in autistic boys ...
... your child at bedtime would be a pitch-black room as ... risk for leukemia.// ,In the past, research has ... for breast cancer, further supporting the theory that light at ... determined that light at night is found to disrupt the ...
... loss may also help prevent prostate cancer from spreading. A ... spread of cancer to the bone and reduce the risk ... bone loss. ,Estimates show prostate cancer spreads to the ... 311 men who were being given hormone therapy for bone ...
... worth of data on breast cancer patients , researchers say ... at diagnosis and those who are diagnosed at a younger ... to die from the disease. Black women are also more ... are those whose tumors are negative for the estrogen receptor. ...
... 2 diabetes could benefit from statins to reduce their risk ... benefits of statin therapy to reduce cardiovascular disease in // ... diabetics who are at an increased cardiovascular risk would benefit ... to look at the effectiveness of statin therapy among type ...
... who have implanted heart-assist devices, such as pacemakers ... .// ,Pacemakers and defibrillators are battery-operated implantable ... as arrhythmia. Researchers say doctors have feared that ... up metal components of the device, dislodge it, ...
Cached Medicine News:
... macular health. Snellen charts available ... Easy to mount on most ... in a few minutes. Rapid ... Retinal vision testing without refraction ...
Eye Q Lite is ideal for color and red-free imaging used in general clinical and optometric casework such as anterior segmenting and diabetic screening....
The Genesis Camera meets the needs of those with specific requirements that cannot be met by a conventional 'chinrest' type camera....
The quick access to diabetic screening, panoramic images of the retina including peripheral area are available by using easy, semi automatic guidance of peripheral fixation....
Medicine Products: